Sanacora, Gerard

Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic

Krystal, J. H., Abdallah, C. G., Averill, L. A., Kelmendi, B., Harpaz-Rotem, I., Sanacora, G., Southwick, S. M., & Duman, R. S. (2017) · Current Psychiatry Reports

Posttraumatic Stress Disorder ResearchTreatment of Major Depression

Cited by 145

Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis

Rhee, T. G., Shim, S. R., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., Papakostas, G. I., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2022) · JAMA Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 141

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study

Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 137

Characterization of GABAergic Marker Expression in the Chronic Unpredictable Stress Model of Depression

Banasr, M., Lepack, A., Fee, C., Duric, V., Maldonado-Aviles, J., DiLeone, R., Sibille, E., Duman, R. S., & Sanacora, G. (2017) · Chronic Stress

Neuroscience and Neuropharmacology ResearchStress Responses and Cortisol

Cited by 135

1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism

Chowdhury, G. M. I., Behar, K. L., Cho, W., Thomas, M. A., Rothman, D. L., & Sanacora, G. (2012) · Biological Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 125

A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders

Wilkinson, S. T., Toprak, M., Turner, M. S., Levine, S. P., Katz, R. B., & Sanacora, G. (2017) · American Journal of Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 125

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Sanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 120

Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial

Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 108

Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder: A Pilot Randomized Placebo-Controlled Trial

Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry

Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 80

Imaging the effect of ketamine on synaptic density (SV2A) in the living brain

Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 78

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.

Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 76

Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study

Leal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 62

Computerized ambulatory monitoring in mood disorders: Feasibility, compliance, and reactivity

Husky, M. M., Gindre, C., Mazure, C. M., Brebant, C., Nolen-Hoeksema, S., Sanacora, G., & Swendsen, J. (2010) · Psychiatry Research

Mental Health Research TopicsDigital Mental Health Interventions

Cited by 62

Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review

Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry

Obsessive-Compulsive Spectrum DisordersTreatment of Major Depression

Cited by 39

mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression

Averill, L. A., Averill, C. L., Gueorguieva, R., Fouda, S., Sherif, M., Ahn, K.-H., Ranganathan, M., D'Souza, D. C., Southwick, S. M., Sanacora, G., et al. (2022) · Journal of Affective Disorders

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 33

Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial

Abdallah, C., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., D'Souza, D. C., Formica, R., Southwick, S. M., Duman, R. S., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory)

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 30

Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder

Holmes, S. E., Asch, R. H., Davis, M. T., DellaGioia, N., Pashankar, N., Gallezot, J.-D., Nabulsi, N., Matuskey, D., Sanacora, G., Carson, R. E., et al. (2023) · Biological Psychiatry

Bipolar Disorder and TreatmentTreatment of Major Depression

Cited by 27

Long-term safety of esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: SUSTAIN-2 phase 3 study

Wajs, E., Leah, A., Morrison, R., Daly, E., Lane, R., Lim, P., Holder, R., Sanacora, G., Young, A. H., Kasper, S., et al. (2019) · European Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 19

S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression

Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Foster, K., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2018) · Biological Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 17

A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine

Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionPain Management and Placebo Effect

Cited by 8